CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Letrozole +1 moredrug
Likely dose
Letrozole 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01353209
NCT01353209Phase 2Completed
CompareCT.gov

Trial of Letrozole in Lymphangioleiomyomatosis

University of Cincinnati·interventional·Posted May 12, 2011·Updated Apr 17, 2024

In Brief

A Phase 2 clinical trial evaluating Letrozole and Placebo for Lymphangioleiomyomatosis. Completed, enrolled 17 participants across 9 sites.

Detailed Summary

The hypothesis in this study is that estrogen suppression by an aromatase inhibitor in postmenopausal women with lymphangioleiomyomatosis (LAM) will prevent or delay progression of lung disease and result in a decrease in the rate of decline in FEV1

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphangioleiomyomatosis
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 12, 2011
Enrollment StartMay 1, 2011
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.1 years ago

Interventions

Letrozoledrug

2.5 mg daily for twelve months

Placebodrug

placebo given daily for twelve months